avelumab + axitinib + palbociclib

This is a combination drug regimen consisting of three agents used primarily in oncology. - **Avelumab** is a human monoclonal antibody targeting PD-L1 (programmed death-ligand 1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune response. - **Axitinib** is an oral small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, thereby blocking tumor angiogenesis and growth. - **Palbociclib** is an oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor that blocks cell cycle progression from G1 to S phase by inhibiting CDK4 and CDK6 activity leading to cell cycle arrest in cancer cells. This triplet combination has been studied in clinical trials for advanced or metastatic clear cell renal cell carcinoma (ccRCC) and advanced non-small cell lung cancer (NSCLC). The combination aims to leverage immunotherapy with antiangiogenic therapy and targeted CDK inhibition for enhanced antitumor efficacy.

Brand names

Bavencio + Inlyta + Ibrance

Other names

avelumab plus axitinib plus palbociclib